Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas?
Object The current treatment for recurrent or malignant meningiomas with adjuvant therapies has not been satisfactory, and there is an intense interest in evaluating new molecular markers to act as therapeutic targets. Enzymes of the arachidonic acid (AA) cascade such as cyclooxygenase (COX)-2 or 5-lipoxygenase (5-LO) are upregulated in a number of epithelial tumors, but to date there are hardly any data about the expression of these markers in meningiomas. To find possible targets for chemotherapeutic intervention, the authors evaluated the expression of AA derivatives at different molecular levels in meningiomas. Methods One hundred and twenty-four meningioma surgical specimens and normal human cortical tissue samples were immunohistochemically and cytochemically stained for COX-2, COX-1, 5-LO, and prostaglandin E receptor 4 (PTGER4). In addition, Western blot and polymerase chain reaction (PCR) analyses were performed to detect the presence of eicosanoids in vivo and in vitro. Resul
Related Questions
- How is Cascade Pilot Personal Edition calculating measuring points for update events > 1s? Are these an average of the chosen update period?
- Is it possible to assign mesh seeds at points which do not follow the uniform / one way bias / two way bias options?
- Are there attacking points in the eicosanoid cascade for chemotherapeutic options in benign meningiomas?
